PMID- 23097669
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121026
LR  - 20240324
IS  - 1687-9112 (Electronic)
IS  - 1687-9104 (Print)
VI  - 2012
DP  - 2012
TI  - Practical approaches to the use of lenalidomide in multiple myeloma: a canadian 
      consensus.
PG  - 621958
LID - 10.1155/2012/621958 [doi]
LID - 621958
AB  - In Canada, lenalidomide combined with dexamethasone (Len/Dex) is approved for use 
      in relapsed or refractory multiple myeloma (RRMM). Our expert panel sought to 
      provide an up-to-date practical guide on the use of lenalidomide in the managing 
      RRMM within the Canadian clinical setting, including management of common adverse 
      events (AEs). The panel concluded that safe, effective administration of Len/Dex 
      treatment involves the following steps: (1) lenalidomide dose adjustment based on 
      creatinine clearance and the extent of neutropenia or thrombocytopenia, (2) 
      dexamethasone administered at 20-40 mg/week, and (3) continuation of treatment 
      until disease progression or until toxicity persists despite dose reduction. 
      Based on available evidence, the following precautions should reduce the risk of 
      common Len/Dex AEs: (1) all patients treated with Len/Dex should receive 
      thromboprophylaxis, (2) erythropoiesis-stimulating agents (ESAs) should be used 
      cautiously, and (3) females of child-bearing potential and males in contact with 
      such females must use multiple contraception methods. Finally, while Len/Dex can 
      be administered irrespective of prior therapy and in all prognostic subsets, 
      patients with chromosomal deletion 17(p13) have less favorable outcomes with all 
      treatments, including Len/Dex. New directions for the use of lenalidomide in RRMM 
      are also considered.
FAU - Reece, Donna
AU  - Reece D
AD  - Princess Margaret Hospital, University Health Network, 610 University Avenue, 
      Toronto, ON, Canada M5G 2M9.
FAU - Kouroukis, C Tom
AU  - Kouroukis CT
FAU - Leblanc, Richard
AU  - Leblanc R
FAU - Sebag, Michael
AU  - Sebag M
FAU - Song, Kevin
AU  - Song K
FAU - Ashkenas, John
AU  - Ashkenas J
LA  - eng
PT  - Journal Article
DEP - 20121014
PL  - United States
TA  - Adv Hematol
JT  - Advances in hematology
JID - 101504271
PMC - PMC3477526
EDAT- 2012/10/26 06:00
MHDA- 2012/10/26 06:01
PMCR- 2012/10/14
CRDT- 2012/10/26 06:00
PHST- 2012/04/05 00:00 [received]
PHST- 2012/08/14 00:00 [accepted]
PHST- 2012/10/26 06:00 [entrez]
PHST- 2012/10/26 06:00 [pubmed]
PHST- 2012/10/26 06:01 [medline]
PHST- 2012/10/14 00:00 [pmc-release]
AID - 10.1155/2012/621958 [doi]
PST - ppublish
SO  - Adv Hematol. 2012;2012:621958. doi: 10.1155/2012/621958. Epub 2012 Oct 14.